MRI in Detecting Heart Damage in Patients With Cancer Receiving Chemotherapy With Exercise Capacity Addendum

PARENT STUDY: Inclusion Criteria: * Receiving \>= 350 mg/m\^2 of Anth-bC therapy, or a combination of Anth-bC (\>= 250 mg/m\^2) and subsequent paclitaxel or Herceptin * Ability to understand and the willingness to sign a written informed consent document Exclusion Criteria: * Intracranial metal, pacemakers, defibrillators, functioning neurostimulator devices, or other implanted electronic devices * Ferromagnetic cerebral aneurysm clips, or other intraorbital/intracranial metal * Allergy to gadolinium or other severe drug allergies * Unstable angina * Significant ventricular arrhythmias (\> 20 premature ventricular contractions \[PVCs\]/minute due to gating difficulty) * Acute myocardial infarction within 28 days * Atrial fibrillation with uncontrolled ventricular response * Moderate or severe aortic stenosis * Claustrophobia * Congestive heart failure (New York Heart Association \[NYHA\] class III or IV) * Significant valvular disease, or significant pulmonary disease requiring supplemental oxygen therapy * Participants unwilling to complete the protocol (24 month duration) * Women who are pregnant * Patients unable or unwilling to provide informed consent EXERCISE CAPACITY ADDENDUM: Inclusion Criteria: * Men and women aged 18-85 with non- or Hodgkin lymphoma or I-IV stage breast cancer patients that expect to receive an anthracycline based chemotherapeutic regimen or other potentially cardiotoxic cancer therapies (e.g. chemotherapy regimens \[anthracyclines, trastuzum…